![]() | Only 14 pages are availabe for public view |
Abstract Hepatocellular carcinoma affects more than 500,000 people globally annually, and five year mortality exceeds 95%. It is the 6th most common cancer of men and the 11th most common cancer of women. The incidence of hepatocellular carcinoma is increasing in many countries. The estimated number of new cases annually is over 500,000 and the yearly incidence comprises between 2.5 and 7% of patients with liver cirrhosis. The incidence varies between different geographic areas, being higher in developing areas; males are predominantly affected, with a 3:2 male/female ratio. The heterogeneous geographic distribution reflects the epidemiologic impact of the main etiologic factors and environmental risk. The Epidemiology of HCC exhibits two main patterns, one in North America and Western Europe and another in Non-Western Countries. In Non-Western Countries HCC is the most common cancer, generally affecting men more than women, and with an age of onset between late teens and 30’s. In Africa; a quarter of the 60 million carriers of hepatitis B virus die either of primary hepatocellular carcinoma or cirrhosis of the liver. Japan has the highest rate of liver cancer in any industrialized country, and the annual death rate of 32 000 In the West, HCC is generally seen as rare cancer, normally of those with pre-existing liver disease. It is often detected by ultrasound screening, and so can be discovered by health-care facilities much earlier than in developing regions such as Sub-Saharan Africa. The incidence of hepatocellular carcinoma (HCC) has increased significantly over the past two decades in the USA; approximately half of this increase is attributed to hepatitis C virus (HCV), while a minimal or no increase has been related to hepatitis B virus (HBV) or alcoholic liver disease. Several factors have been identified as being related to the etiology of HCC. In many cases, these factors, such as chronic viral hepatitis, alcoholism, hemochromatosis, also causes chronic liver diseases and cirrhosis. |